Natera reported third-quarter revenues of $794 million, a 34% increase from the prior year period, driven by higher test volumes and average selling price improvements. The company processed approximately 1.09 million tests, including over 339,500 oncology tests. Natera raised its full-year 2026 revenue guidance midpoint by $140 million to between $3.005 billion and $3.035 billion. The firm reported a net loss of $59.9 million for the quarter, narrowing from $87.5 million in the year-ago period. Natera operates as a global leader in cell-free DNA and precision medicine diagnostics.
